Overall survival (OS) in men with chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC) receiving bicalutamide (BIC) followed by enzalutamide (ENZA) or abiraterone (ABI).

Authors

Daniel J. George

Duke University School of Medicine, Durham, NC

Daniel J. George , Scott T. Tagawa , Stanislav Lechpammer , Dave Russell , Agnes Hong , Jack Mardekian , Ahong Huang , Li Wang , Nora Janjan , Krishnan Ramaswamy

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2024 ASCO Genitourinary Cancers Symposium

bookmark_border

Real-world treatment (Tx) sequences and time to discontinuation (rwTTD) in the first-line (1L) metastatic castration-resistant prostate cancer (mCRPC) setting.

First Author: Emily Nash Smyth

insert_chart_outlined

Poster

2021 Genitourinary Cancers Symposium

bookmark_border

Real-world clinical outcomes study of sequential novel antihormonal therapy (NAH) or radium-223 (Ra-223) treatment of metastatic castration-resistant prostate cancer (mCRPC) that progressed after first-line NAH.

First Author: Oliver A. Sartor

insert_chart_outlined

Poster

2019 Genitourinary Cancers Symposium

bookmark_border

Clinical outcome with concurrent or layered treatment with radium-223 and abiraterone: A retrospective study of real-world experience with patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).

First Author: Daniel J. George

insert_chart_outlined

Poster

2017 Genitourinary Cancers Symposium

bookmark_border

Real-world outcomes in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) receiving second-line (2L) chemotherapy (CT) vs alternative androgen receptor-targeted agents (ARTA) after lack of response to first-line (1L) ARTA in US community oncology practices.

First Author: William K. Oh